Ketanest

Esketamine hydrochloride, the active ingredient in Ketanest, is a NMDA receptor antagonist presented as an injectable solution for intramuscular or intravenous use. It provides dissociative anesthesia and analgesia for induction of anesthesia and procedural sedation in surgical and diagnostic settings, achieving rapid onset of unconsciousness and patient comfort.

GNH USA supplies Ketanest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product is manufactured under EU standards and is classified as a Schedule III controlled substance.

Ketanest (esketamine) is employed in anesthesia and sedation pathways to achieve rapid dissociative anesthesia.

Induction of anesthesia: rapid onset unconsciousness for surgical procedures Procedural sedation: provides analgesia and sedation for minor surgeries and diagnostic interventions Pain management during surgery: contributes to multimodal analgesia reducing opioid requirement

Ketanest may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dissociation or feeling of unreality - Elevated blood pressure - Increased heart rate - Nausea - Vomiting - Dizziness

Serious or Rare Side Effects: - Respiratory depression - Severe hypertension - Psychotomimetic reactions (hallucinations, agitation) - Allergic reactions (anaphylaxis) - Elevated intracranial pressure

When using Ketanest, clinicians should observe several safety measures.

Patient selection: assess cardiovascular status before use Monitoring: continuous vital sign and respiratory monitoring required Drug interactions: avoid concurrent CNS depressants History of psychiatric disorders: use with caution Pregnancy and lactation: avoid unless benefits outweigh risks Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Ketanest can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Concomitant use with other NMDA antagonists: risk of additive neuropsychological effects - Potent CYP2B6 inhibitors: may increase esketamine plasma levels - Monoamine oxidase inhibitors: risk of hypertensive crisis

Moderate Interactions (Monitor Closely): - Benzodiazepines: may blunt desired anesthetic effect - Opioids: synergistic respiratory depression - Alcohol: enhanced CNS depression - Sympathomimetic agents: may exacerbate hypertension